All News about Lexaria Bioscience Corp
Lexaria (NASDAQ: LEXX) Advances Human Nicotine Study, Announces New Program with Altria
April 19, 2022
Topics
Intellectual Property
Exposures
Intellectual Property
![](https://investorplace.com/wp-content/uploads/2021/11/shutterstock_1667119063.png)
![](https://cdn.benzinga.com/files/images/story/2022/04/14/aapharma_8.png?width=1200&height=800&fit=crop)
Why Lexaria Shares Are Rising Today
April 14, 2022
Via Benzinga
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg?v=0)
Via AccessWire
![](https://cdn.benzinga.com/files/images/story/2022/04/18/screenshot_2022-04-18_at_11.43.40_pm.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/04/18/yesterdays_movers.png)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_6599.jpeg?width=1200&height=800&fit=crop)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg?v=0)
![](https://cdn.benzinga.com/files/images/story/2022/04/13/screenshot_2022-04-14_at_12.24.37_am.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/04/12/screenshot_2022-04-13_at_12.37.02_am.png?width=1200&height=800&fit=crop)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg?v=0)
Lexaria Provides Update on Human Nicotine Study NIC-H22-1
April 12, 2022
Via AccessWire
![](https://cdn.benzinga.com/files/images/story/2022/04/11/screenshot_2022-04-11_at_11.13.28_pm.png?width=1200&height=800&fit=crop)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/1529.jpg?v=0)
Via AccessWire
![](https://cdn.benzinga.com/files/images/story/2012/screenshot_2022-04-01_at_12.39.04_am.png?width=1200&height=800&fit=crop)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.